Statistics on Biotechnology Use  
Results by fields of operation
Company sector.  Biotechnology results by main variables by whichever Biotechnology activities are the main ones, secondary or a tool necessary for production
Unidades: specified in variables

;Total;Main;Secondary dwellings;Tool;
Companies that carry out R&D in Biotechnology;1.233;615;178;440;
%Companies according to biotechnology used: Genetic code;31,7;40,8;21,9;22,8;
%Companies according to biotechnology used: Functional units;38,5;45,5;38,3;28,8;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;22,8;28,2;21,2;15,7;
%Companies according to biotechnology used: Bioprocesses;53,4;46,9;57,3;60,8;
%Companies according to biotechnology used: Sub-cellular organisms;8,6;12,5;5,2;4,6;
%Companies according to biotechnology used: Bio-computing;22,3;31,7;15,1;12;
%Companies according to biotechnology used: Nanobiotechnology;10,6;13,9;15,2;4,3;
%Companies according to biotechnology used: Other;14,2;14,8;17,1;12,2;
%Company by field(s) of ultimate application of biotechnology use: Human Health;46,3;63;37,1;26,6;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;16,2;19,7;16,9;11,2;
%Company by field(s) of ultimate application of biotechnology use: Food products;32;24,2;29,9;43,9;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;24,6;22,5;30,1;25,3;
%Company by field(s) of ultimate application of biotechnology use: Environment;15,5;13,7;26,8;13,4;
%Company by field(s) of ultimate application of biotechnology use: Industry;12,9;14,3;22,6;6,9;
Personnel in R&D in biotechnology (no. of persons);13.444;7.243;1.822;4.379;
Personnel in R&D in biotechnology (no. of persons): Researchers;7.378;4.139;1.032;2.207;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;6.066;3.105;790;2.171;
Personnel in R&D in biotechnology (no. of persons): women;7.501;4.255;917;2.329;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;4.052;2.352;542;1.158;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;3.450;1.903;376;1.171;
Personnel in R&D in biotechnology (FTE);9.401,9;5.696,8;1.025,3;2.679,9;
Personnel in R&D in biotechnology (FTE): Researchers;5.398,3;3.332,7;675,7;1.389,9;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;4.003,6;2.364,1;349,5;1.290;
Personnel in R&D in biotechnology (FTE): women;5.426,2;3.428,5;556,8;1.440,9;
Personnel in R&D in biotechnology (FTE): (women) Researchers;3.016,4;1.924,6;360,1;731,7;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;2.409,8;1.503,9;196,7;709,2;
Internal expenditure on R&D (thousands of euros);897.333;602.520;77.601;217.211;
1) By nature of the expense: Current expenses;817.409;541.269;71.986;204.154;
1.1) Remuneration to researchers;295.705;194.401;32.922;68.382;
1.2) Remuneration to technicians and assistants;156.853;98.937;11.856;46.060;
1.3) Other current expenses;364.852;247.931;27.209;89.712;
2) By nature of the expense: Capital expenses;79.924;61.251;5.615;13.057;
2.1) Land and buildings;10.272;8.482;898;892;
2.2) Equipment and instruments;56.609;41.244;4.323;11.043;
2.3) Acquisition of specific R+D software;4.839;4.254;109;476;
2.4) Otros productos de propiedad intelectual específicos para I+D;8.203;7.271;286;647;
1.1) By origin of the funds: Own funds;613.097;418.567;47.014;147.516;
1.2) By origin of the funds: From companies;86.085;44.282;10.408;31.395;
1.3) By origin of the funds: Public Administration funds;92.140;56.901;11.393;23.846;
1.4) By origin of the funds: From Universities;853;519;0;335;
1.5) By origin of the funds: From non profit private institutions;4.682;1.965;0;2.717;
1.6) By origin of the funds: Foreign funds;100.476;80.287;8.786;11.403;
Purchase of R&D services in biotechnology (thousands of euros);85.011;62.516;14.617;7.878;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;54.243;36.965;11.023;6.255;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;30.768;25.552;3.594;1.622;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;39,2;48,3;36,5;27,7;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;11,7;10,9;15,3;11,4;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;12,5;12,7;12,8;12,1;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;10,9;12;9,4;9,9;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;14;16;14;12;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;17;21;15;11;
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;15;16;15;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;36;42;35;27;
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;47;53;44;39;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;19;21,8;17,6;15,6;
% Companies that have requested biotechnology patents;17;25;16;7;
Number of patents requested;681;473;65;144;
% Companies with income of an international origin related to biotechnological activities;23;28,9;17,9;17;
% Turnover representing income of an international origin related to biotechnological activities;1,6;9,4;0,1;0,6;
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;56;56;74;49;
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;44;44;26;51;
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;84;82;82;96;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;14,7;17,1;2;0,4;
% Income of an international origin related with activities according to the classification: Operating source abroad;0,8;0,2;15,5;1,6;
% Income of an international origin related with activities according to the classification: Other;0,6;0,5;0,2;1,5;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute